following the Irish National Cancer Control Program (NCCP), National Strategy for Cancer Control 2006.
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While radical prostate surgery has evolved greatly over the past decade, with a variety of techniques now established in urological practice, open radical prostatectomy remains a common procedure. Surprisingly, however, there is a paucity of data regarding Irish outcomes of this approach.
The aim of the present study was to evaluate the oncological outcomes of patients undergoing open radical retropubic prostatectomy (RRP) performed by a single surgeon across three centers in Ireland.
Methods
All patients who underwent open RRP, with or without pelvic lymph node dissection (PLND), performed by a single surgeon (D.J.G.) between September 2011 and November 2016 were included. Surgery was performed on one of three sitesThe Mater Misericordiae University Hospital, St. Vincent's University Hospital, and St. Vincent's Private Hospital, all located in Dublin, Ireland.
Our practice is to offer surgical treatment to all patients with non-metastatic prostate cancer considered fit for surgery, having counseled them as to alternative options, including radiotherapy (with external beam radiotherapy or brachytherapy discussed by a radiation oncologist) and, where appropriate, active surveillance (AS). The absence of metastatic disease is confirmed on clinical assessment and radiological staging with multiparametric MRI prostate with additional isotope bone scan þ/À CT (computed tomography) TAP (thorax abdomen pelvis) in patients with Gleason score > 7 on biopsy or prostate-specific antigen (PSA) !10 mg.
The decision to perform pelvic lymph node dissection (PLND) is based on preoperative predicted rates of lymph node positivity, for which we routinely use Memorial Sloan Kettering Cancer Centre (MSKCC) nomograms, 6 proposing PLND to patients in categories with !5% estimated rates of nodal positivity. The form of lymphadenectomy performed during the study period was standard PLND, comprising obturator and external iliac nodal basins with extended nodal dissection (ePLND) performed on selected patients (generally prompted by young age or significant burden of high grade disease). A nerve-sparing approach is attempted where clinical staging (taking into account preoperative imaging and intraoperative findings) is estimated at T2; patients with !T3 diseases are considered for a unilateral nerve-sparing approach on the contralateral side in cases where extracapsular extension is appreciated on one side of the gland only. All patients are discussed postoperatively at a urology multidisciplinary team (MDT) meeting, with decision for further treatment, primarily adjuvant radiotherapy, made in this forum. Standard follow-up comprises clinical review with a PSA reading at 3-months and then 6 monthly for 2 years, assuming biochemical recurrence is not detected. Annual PSA monitoring is adopted thereafter.
A retrospective electronic chart review of all patients was performed. Preoperatively recorded data included: patient age at diagnosis, clinical stage on digital rectal exam, preoperative prostate-specific antigen (PSA) level, Gleason's score and number of positive cores at transrectal ultrasound guided (TRUS) biopsy, and modality and results of imaging performed for radiological staging. The date of surgery and decision regarding the need to perform PLND was documented. Final histopathological results were reviewed with pathological Tstage, Gleason's score, nodal status, and surgical margin status recorded. Surgical margin status was defined as the presence of tumor at the inked surface of the specimen 7 and classified as focal ( 3 mm) or extensive (!3 mm or multifocal) based on stratification proposed by other authors. 8, 9 All patients' oncological outcome was ascertained by review of PSA at last follow-up, and/or imaging findings were relevant. Where a PSA value within the previous 12 months was not available from the chart, an attempt to obtain more recent follow-up data was made by telephoning the patient's general practitioner. Biochemical recurrence was defined as two rising PSA readings !0.05. Postoperative radiotherapy was defined as adjuvant if the decision to administer radiotherapy was made at the postoperative MDT meeting (in which case treatment was typically commenced at 4 to 6 months postoperatively) and as salvage if the patient was referred for radiotherapy in response to rising PSA levels where the MDT decision had been for surveillance in the first instance. A pelvic lymph node dissection was performed in 118/265 (44.25%) with mean number of nodes retrieved 6.08 (range: . Lymphadenectomy data are outlined in ►Table 4. Of 104 patients staged pN0 (pathologically node negative), 4 had had radiological suspicion of nodal involvement preoperatively. Of At most recent follow-up, 238/265 (89.81%) of patients were disease-free of whom 24/238 (10.08%) had received adjuvant and 17/238 (7.14%) received salvage radiotherapy, and no patients had died of prostate cancer. Of the overall cohort, 33/265 (12.45%) of patients received adjuvant therapy. Of patients that did not receive adjuvant therapy up front (n ¼ 232), 32 patients (13.79%) were ultimately referred for salvage therapy. Either adjuvant or salvage treatment (radiotherapy or androgen deprivation therapy) was ongoing in 19/265 (7.17%) of patients. Mean overall follow-up was 32.24 months (range: 8-72 months).
Results
Overall oncological outcomes relative to preoperative PSA, pathological T and N-stage, final Gleason's score and surgical margin status are outlined in ►Tables 6-8. 
Discussion
To date, there has been a paucity of data pertaining to outcomes of radical prostatectomy in Ireland. The only other recently published paper relating to overall outcomes of Irish prostatectomy assesses results of 125 consecutive robot assisted cases with excellent early outcomes at 1 year.
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Open RRP, however, remains a common operation outside of robotic centers in North America and Europe, and debate continues as to whether an open or robotic approach to radical prostatectomy confers a clear benefit in oncological or functional outcomes. With regard to preoperative cancer grading, based on diagnostic trans-rectal ultrasound (TRUS) biopsy, the majority of our RRP patients (139/265, 52.4%) were categorized as harboring Gleason's score 7 (3 þ 4 or 4 þ 3) disease, followed by Gleason's score 8 (27.38%, n ¼ 72). Only a minority (28/265, 10.56%) carried a preoperative diagnosis of Gleason's score 6 disease. We note a different pattern in the literature, with a predominance of patients with preoperative Gleason's scores 6 in cohorts undergoing RRP, as outlined in ►Fig. 1.
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This may reflect higher grade disease at presentation, an aggressive surgical approach where all high risk patients with nonmetastatic disease are offered surgery and/or the fact that a large proportion of patients with Gleason's 6 disease at our institutions meet the criteria for active surveillance (AS) protocols, and it is the senior author's practice to offer AS to such patients, reflecting a shift in management strategy from that employed in historical series.
Discordance between Gleason score based on diagnostic TRUS biopsy and that reported from the prostatectomy specimen is a recognized phenomenon. Predictors described include the number of biopsy cores and prostate weight, 17 the PSA density 18 and the reporting of the specimen by a uropathologist. 19 The international literature suggests an overall upgrading rate of 29 to 50.5% and an overall downgrading Oncological Outcomes of Open Radical Prostatectomy Croghan et al. e230
(3 þ 4) was the most common alteration in final histology. 20 We noted a 27% (71/263) downgrade rate which is within the range reported. While our specimens are reported as "overall Gleason's score (components)," in acknowledgement of the Gleason's grades incorporated at the 2014 International Society of Urological Pathology (ISUP) consensus conference, 23 we considered Gleason's 7 (3 þ 4) and Gleason's 7 (4 þ 3) as different grade groups and documented changes between these categories as upgraded or downgraded accordingly.
On histopathological review of the prostatectomy specimen, 170 patients (64.15%) had pT2 disease and 95 patients (35.85%) had pT3 disease. A higher proportion of our patients had pT3 disease than those reported in several large U.S. Alemozaffar et al (n = 621) 13 Liu et al (n = 249) 15 Schiavina et al (n = 430) 14 Simon et al (n = 1,001) 16 Mullins et al in PSA era (n = 3,385) 33 for example, also frequently used. Of patients undergoing pelvic lymph node dissection, our 11.86% (14/118) detection rate of nodal metastases is higher than that reported in other studies (reported rates range: 3.4-9.65%) [12] [13] [14] 31, 34 This may reflect both higher proportions of more aggressive or locally advanced disease in this cohort compared with that of other series, as discussed above, and also a lower overall PLND rate suggesting a more stringent criteria for proceeding to nodal dissection. We noted no complications specific to lymph node dissection. During the study period, routine protocol was to perform a standard bilateral nodal dissection, with extended dissections (ePLND) performed in selected cases. We are now moving toward extended pelvic lymph node dissection (ePLND) as the standard of care. Eighteen patients whose final histology was N0 or Nx with a clear surgical margin had a biochemical recurrence. Of this subgroup 11/18 (61.12%) are disease-free postsalvage therapy, 2/18 (11.12%) alive with disease and 5/18 (27.78%) continue to undergo treatment. Mean preoperative PSA was 12.22 (range: 4-30) which was higher than the mean PSA for all patients (9.46). Of the18 patients, 9 (50%) had high-risk Gleason's 8 or 9 disease, and the remainder Gleason's 7 disease. Again, 8/18 (44.45%) had pT3 disease (T3a in 5/8 and T3b in 3/8), all of whom underwent PLND and were staged pN0. Furthermore, 10/18 had pT2 disease (pT2c in 9/ 10), 5/10 underwent PLND and were staged N0, and 5/10 did not undergo PLND. It is unclear why this cohort experienced biochemical recurrence (BCR), although one possible explanation is that patients harbored low volume nodal metastases in nodes that were not retrieved at PLND. The number of nodes retrieved in the 13 patients in this cohort who underwent PLND (mean: 6.7 ; median 4 nodes) was similar to that in our overall study population but we acknowledge higher reported nodal retrieval in some studies. 34 We plan to re-evaluate rates of recurrence in pN0R0 patients having implemented ePLND to explore this hypothesis.
PSMs have been shown to be independently associated with increased rates of biochemical recurrence, [35] [36] [37] [38] although their influence on prostate cancer specific mortality is debated. 39 Our overall rate of margin positivity was Of patients with PSMs, 33.8% (24/71) received adjuvant therapy following MDT discussion. In the later years of the study period, adjuvant therapy was administered if further high-risk features in addition to a PSM were present. Of those managed by close clinical and biochemical follow-up as opposed to adjuvant therapy, 14/47 (29.8%) had biochemical recurrence and were referred for salvage therapy and 33/47 (70.21%) were disease-free with no additional treatment at last follow-up. While follow-up is not yet adequate to draw definitive conclusions, we feel that PSMs alone should not prompt automatic administration of adjuvant therapy, and evidence from other experiences would support this.
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Our results found 243 patients to have completed treatment and have available follow-up data. Of these, 238 (97.9%) were disease-free at last follow-up. Overall, 238/ 265 (89.81%) of patients were disease-free at the last follow-up (mean 32.24 months), of whom 24/238 (10.08%) had received adjuvant and 17/238 (7.14%) received salvage radiotherapy. Adjuvant/salvage treatment was ongoing in 19/265 (7.17%) of patients, two patients died of unrelated causes, one patient was lost to follow-up and five patients were alive with incurable disease. No patients in this series had died from prostate cancer, although we acknowledge follow-up is short for this outcome. Heterogeneity of populations and disease, variable definitions of biochemical recurrence, and differing practices in administration of adjuvant and salvage radiotherapy make outcomes difficult to compare between studies. Nonetheless, our results to date seem broadly similar to those published in the literature. Early outcomes of anatomical open RRP reported by Catalona et al (n ¼ 925) suggest an overall 5-year progression-free survival probability of 78%. 44 More recent outcomes reported post RRP include those of Alemozaffar et al (3-year recurrence-free survival of 89.9%, n ¼ 493), 13 10 We defined BCR as the finding of two PSA readings !0.05 ng/mL and demonstrating a rising trend. This is a lower threshold than used by other authors who stipulate, for example, levels of !0.2 ng/mL 12,35,43 or higher 37 before declaring BCR. We would typically refer patients fitting our definition for early salvage radiotherapy and therefore have defined BCR as such. We acknowledge several limitations to our study. Our follow-up data are insufficient to capture cases of late biochemical recurrence, as is a recognized phenomenon. 45, 46 For this reason, we keep our patients on annual PSA surveillance as a lifelong measure once they are disease-free for 5 years. Our posttreatment follow-up is further limited in the salvage radiotherapy subgroup due the latency to biochemical recurrence and further time to treatment completion within the study period. We did not record blood loss, transfusion rates, or operative time as these were not uniformly recorded in the computerized records across the hospital sites. Functional outcomes were not assessed. We recognize this as an inherent study weakness; however, these were not recorded in a standardized fashion during the study period and we feel retrospective evaluation of them would therefore lack accuracy. We therefore focused on our primary outcome of oncological results.
Conclusion
Good oncological outcomes of RRP are seen in this 5-year review with the majority of patients experiencing biochemical-free survival at most recent follow-up. This study adds Irish data to the international literature on prostate cancer disease characteristics in a selected surgical cohort and on outcomes of open radical prostatectomy.
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